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One of the  two  mutations  responsible  for  the classical 
infantile  Jewish  form of Tay-Sachs  disease  is a four- 
base  insertion  in  exon 11 of the  &hexosaminidase a 
subunit gene. The gene is known to be transcribed 
normally,  but  the mRNA is essentially  undetectable. It 
is not clear why  such a relatively  minor  abnormality 
results  in complete failure  to  generate  stable mRNA. 
The four-base  insertion  was  introduced  into the  normal 
&hexosaminidase cDNA by  site-directed  mutagenesis. 
When COS- 1 cells were  transfected  with  the  resultant 
mutant cDNA, it  generated  stable mRNA and a trun- 
cated,  relatively  stable  but  catalytically  inactive  en- 
zyme protein. The mutant enzyme protein was not 
processed nor  released  into  the  culture medium. The 
mutant cDNA also generated the truncated enzyme 
protein in an in vitro translation  system  with  rabbit 
reticulocyte  lysate. COS-1 cells transfected  with a 3‘ 
end of the  gene  segment,  from  intron 8 through  the 3‘ 
terminus,  generated processed RNA of approximately 
2 kilobases, the size expected from normal splicing, 
irrespective of presence or absence of the  four-base 
insertion in exon 11. These  results  indicate  that  the 
four-base  insertion does  not  destabilize  properly 
spliced mRNA, nor  does it  interfere  with  normal splic- 
ing of the  transcript, at least  in  the  expression  system 
utilized. If the  four-base  insertion  is responsible for 
the undetectable mRNA in the mutant cells, it must 
interfere  with some other  steps  in  the processing/splic- 
ingltransport of the  primary  transcript  yet  to  be  ex- 
amined. On the  other  hand,  the possibility cannot  be 
excluded definitively that another still unidentified 
abnormality  in  the  same  allele might  be  responsible  for 
the  nearly complete  absence of mRNA. 
Two  mutations  in  the  p-hexosaminidase a subunit gene are 
known to be responsible for almost all cases of classical 
infantile  Tay-Sachs disease occurring  among  the Ashkenazi 
Jewish population, a splicing defect at  the 5’ donor site of 
intron 12 (1-3) and a four-base  insertion  in exon 11 (4). Both 
mutations  result  in a nearly  undetectable level of mRNA,  but 
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t t? mRNA derived from  the splicing  defect can be visualized 
in overloaded Northern  blots as a diffuse smear  (3), while the 
mRNA  from  the allele with  the  four-base  insertion is even 
harder  to  detect. 
Paw  and Neufeld ( 5 )  earlier  demonstrated  that P-hexosa- 
minidase a gene is normally transcribed  in  infantile  Jewish 
patients,  all of whom later were found  to be homozygous for 
the  four-base  insertion (6). How the  primary  transcripts  with 
the  small  insertion  within  an  exon away from  splice junctions 
fail to  generate  stable  mRNA is not clear. But,  the four-base 
insertion  must somehow either  interfere  with  normal process- 
ing  and  transport of primary  transcripts  or destabilizes nor- 
mally  spliced  mRNA. 
Experiments described in  this  report were designed to  ad- 
dress  the above question. The results  indicate  that  the four- 
base  insertion does not destabilize properly spliced mRNA, 
nor does it interfere with normal splicing of several exons 
flanking exon 11. The results still leave a possibility for 
another  unidentified  abnormality  in  the  same allele that  is  in 
fact responsible for the absence of stable  mRNA. 
MATERIALS  AND  METHODS 
Construction of the Mutant p-Hexosaminidase a Subunit cDNA 
with the  Four-base Insertion-Since the  mutant @-hexosaminidase a 
subunit  cDNA  with  the four-base insertion  cannot be obtained  from 
natural sources, the insertion was introduced into the normal p- 
hexosaminidase a cDNA clone (7) by site-directed  mutagenesis  using 
a commercially available mutagenesis kit (MutaGene phagemid in 
GAACCGTATATC-CTATGGCCCTGA-3’) according to the 
vitro mutagenesis kit: Bio-Rad) and a 28-mer oligonucleotide (5’- 
procedure provided by the manufacturer. The mutagenized cDNA 
was transferred  from  the  phagemid pTZ18U to a eukaryotic  expres- 
sion vector, pSVL  (Pharmacia  LKB Biotechnology Inc.). The  muta- 
genized sequence was confirmed by sequencing  pSVL subclones  using 
a  21-mer primer (5’-GTGTGGCGAGAGGATATTCCA-3’) which 
hybridized at about 100-bp’ upstream of the mutagenized site.  Except 
for the  insertion,  the  normal  and mutagenized 6-hexosaminidase a 
cDNAs were identical  with a 60-bp  5’-untranslated sequence. 
Expression in COS-1 Cells-Transformed African green monkey 
kidney  cells (COS-1) were purchased  from  the American Type  Culture 
Collection  (Rockville, MD). The cells were transfected with the 
normal and mutagenized  @-hexosaminidase  cDNAs in the pSVL 
vector by the DEAE-dextran-mediated procedure (8) or by a com- 
mercial reagent utilizing liposomes (Lipofectinm Reagent, Bethesda 
Research  Laboratories)  (9).  When  the Lipofectin@ reagent was used, 
the period of transfection was  5  h with 2 pg of plasmid DNA  and 50 
pl of the Lipofectin reagent  per  60-mm  dish.  At 48  h after  transfection, 
the cells were harvested for further experiments. All transfection 
experiments were done  multiple  times,  each  sample  in  duplicate  or 
triplicate  to  assure reproducibility of results. 
Northern Analysis-Total RNA was prepared from 10 100-mm 
culture  dishes of transfected  COS-1 cells and  treated  with  RNase- 
free DNase-I (Promega Corp., Madison, WI) in order to remove 
contamination by the  cDNA  (10).  Poly(A)+ RNA, 1.5 pg, was electro- 
phoresed  in 1% agarose/formaldehyde denaturing gel and  transferred 
’ The abbreviations used  are:  bp,  base pair(s); kb, kilobase(s). 
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to GeneScreen Plus nylon membrane  (Du  Pont-New  England  Nuclear 
Research Products). Hybridization with the full-length normal 8- 
hexosaminidase a subunit cDNA  labeled  with [n-:”P]dCTP by nick- 
translation  and  subsequent washings were carried  out according to 
the  instructions of the  manufacturer.  Blots were exposed to Kodak 
x-ray film a t  -70 ‘C using a Cronex Hi-Plus  intensifying screen. 
Enzymatic Assays-Total @-hexosaminidase  activities  and  the  ac- 
tivities of the A isozyme were determined  on  total homogenates of 
COS-1 cells. 4-Methylumbelliferyl@-N-acetylglucosaminide was  used 
as a substrate for the  total activity, and 4-methylumbelliferyl 8-N- 
acetylglucosamine 6-sulfate for the A isozyme (11). 
Biosynthesis and Processing Studies of Enzyme  Protein with Im- 
munoprecipitation-At 48  h after  transfection,  COS-1 cells in 60-mm 
dishes were labeled for 2 h with 0.5 mCi of [4,5-:‘H]leucine (ICN 
Riomedicals, Irvine, CA). Cells were harvested either after 2 h of 
labeling to  assess  the  synthetic  activity or after a  24-h chase period 
following the 2-h labeling. For the  chase  experiments, 0.1 ml of an 
unlabeled  leucine  solution,  5 mg/ml, was  added after  the 2-h labeling 
period. The  culture medium  was  collected after 24-h labeling in  the 
presence of  20 mM NH4C1. Subsequent  extraction of cellular protein, 
immunoprecipitation  with  anti-hexosaminidase A antiserum,  the 
polyacrylamide gel electrophoresis, and visualization by autoradiog- 
raphy were performed  according to published  procedures with  minor 
modifications  (12,  13). 
In  Vitro Translation-The normal  and mutagenized  P-hexosamin- 
idase n subunit  cDNAs were subcloned into  the pGEM-3Zf(-)  vector 
(Promega Corp., Madison, WI). After linearization of the  plasmid by 
Hind111 digestion, in vitro transcription was carried out using T7 
RNA  polymerase (Promega)  with a capping analogue (10).  Transla- 
tion  in vitro was then  done using the  rabbit reticulocyte lysate  system 
(Bethesda Research Laboratories) with 0.3 pg of the  transcript  and 
10 pCi of Trans:’”S-label (ICN Biomedicals). One-sixth of the  trans- 
lation  products was subjected to polyacrylamide gel electrophoresis. 
The procedures subsequent to  the electrophoresis were the  same  as 
those for the synthesis/processing studies above. 
Splicing of Genomic Segment-A genomic segment encompassing 
approximately 6  kb of the 3’ terminus of the  normal  @-hexosamini- 
dase (Y subunit gene was kindly  provided by Dr. Richard Proia 
(NIDDK,  The  National  Institutes of Health,  Bethesda,  MD).  It was 
the  segment designated as  E6 by Proia  and  Soravia  (14)  in pUC 13. 
It included  most of intron 8 without  the 5’ donor  site  on  the 5’ end 
and  the  entire  downstream  portion of the gene through exon 14. This 
entire genomic sequence was used as  the  “normal gene.” A similar 
genomic fragment in pTZ18 that included the four-base insertion  in 
exon 11 was  kindly  provided by Dr. Rachel  Myerowitz (NIDDK,  The 
National  Institutes of Health,  Bethesda,  MD). A  276-bp KpnI frag- 
ment  containing  the four-base insertion was  excised and exchanged 
with the normal KpnI fragment in the E6 clone to construct the 
“mutant gene.” Thus,  the  construct for the  “mutant gene”  was iden- 
tical  with the  “normal gene” except for the presence of the four-base 
insertion.  Both  normal  and  mutant sequences were ascertained by 
sequencing them  with  two  primers which  hybridized to  exon 11 and 
intron 12,  respectively  (15). The  primer sequences were 5’- 
GTGTGGCGAGAGGATATTCCA-3’ and  5”TGGCTAGATGG- 
GATTGGGTCT-3’.  These  normal  and  mutant gene segments were 
subcloned into  the EcoRI site of pGEM-7Zf(+) vector, transferred  to 
the pSVL eukaryotic expression  vector  using  XhoI and  BamHI  sites, 
and used to transfect  COS-1 cells as described  above  except that  10 
pg of plasmid DNA and 450 pl of Lipofectin reagent were used per 
100-mm dish. Cells were harvested and the Northern analysis was 
carried out  as described above. 
RESULTS 
Northern Analysis-The COS-1 cells transfected  with  the 
pSVL vector containing  the mutagenized  cDNA  expressed the 
human @-hexosaminidase a mRNA of apparently  normal size 
and  quantity (Fig. 1). The size of both  the  control  and  mutant 
mRNA (approximately 2.3 kb) was larger than  the ndogenous 
mRNA  in  human cells (2 kb), probably  reflecting the  distance 
between the  transcription  initiation  site of the vector and  the 
5’ terminus of the  inserted cDNA. 
Mutant @-Hexosaminidase CY Protein-Increased amounts 
of an immunoprecipitable protein with an apparent M, of 
47,000 were detected in both the pulse-labeled and chased 
COS-1 cells transfected with the mutagenized  cDNA, while 
rri) 
FIG. 1. Northern blotting analysis of @-hexosaminidase a 
subunit mRNA expressed in COS-1 cells. Methodological details 
are described in  the  text.  Each lane contains 1.5 pg of  poly(A’) RNA 
extracted from COS-1 cells transfected with the pSVL vector con- 
taining either the normal or mutant cDNA. The size of the main 
mRNA band is approximately 2.3 kb as  estimated by a mixture of 
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FIG. 2. Synthesis and processing of expressed 8-hexosamin- 
idase a subunit in COS-1 cells ( A )  and in an in vitro transla- 
tion system ( B ) .  A, the lanes  from  mock-transfected  cells provide 
information on  endogenous  @-hexosaminidase as well as on proteins 
nonspecifically precipitated by the  antiserum.  In COS-1 cells trans- 
fected with pSVL that contained the normal &hexosaminidase n 
subunit cDNA, the  synthesized  67-kDa  precursor cy protein  (2-h pulse) 
is processed to  the 54-kDa mature  protein  (24-h  chase). On the  other 
hand,  in COS-1  cells transfected with the vector containing  the 4-bp 
insertion  mutant cDNA,  a truncated 47-kDa protein  is synthesized. 
Its size remains  the  same  after  the 24-h chase period, and  it does not 
appear  in  the  culture medium. The  mutant  protein  is indicated by 
arrows. R, in vitro translation  products  are 61  kDa from the normal 
(Y subunit cDNA and 47-49 kDa from the 4-bp insertion  mutant a 
subunit cDNA. The numbers between the two figures are positions of 
the  protein molecular  size standards, while those  on  the outside are 
estimated sizes of the enzyme proteins generated by the normal or 
mutagenized cDNAs. 
all other  bands  appeared  similar  to  those  in mock-transfected 
cells (Fig. 2 A ) .  As expected, the cells transfected with the 
normal cDNA synthesized the precursor protein with an 
apparent size of 67 kDa which was then processed to a smaller 
mature form during the chase period. When corrected for 
radioactivity present in the mock-transfected sample, the 
quantity of the  mutant 47-kDa protein was approximately 
15-20% of the  normal  precursor enzyme protein synthesized 
in  the cells transfected  with  the  normal cDNA. The  synthe- 
sized mutant enzyme protein was not processed during  the 
chase period, nor was it excreted to  the  culture media in the 
presence of ammonium chloride. Furthermore,  the  apparent 
size difference of 20,000 between the normal and mutant 
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precursor  proteins  is  too large to be accounted for by the 99- 
amino acid  difference. This  finding suggests that  the  mutant 
enzyme protein may not be glycosylated. I n  vitro translation 
of the  normal  and mutagenized cDNA was consistent  with 
this  interpretation (Fig. 2B). The  apparent size of the  normal 
pro-precursor  polypeptide was 61,000 kDa, substantially 
smaller  than  that of the  precursor  found  in COS-1 cells, while 
that  of the  mutant was 47,000-49.000 kDa, similar  to  that  in 
the cells. From  the  quantity of the  precursor  protein  synthe- 
sized in  the 2-h labeling  period and  the  quantity  remaining  in 
the chased  sample, the  mutant  protein  appeared  to be synthe- 
sized a t  a reduced rate but relatively stable. On the other 
hand,  the  rate of translation  appears  to be normal  in  the  in 
uitro translation  experiment. 
The COS-1 cells transfected with the normal cDNA ex- 
pressed about three times normal total @-hexosaminidase 
activity  and  about 10 times  normal A isozyme activity (Fig. 
3). However, the @-hexosaminidase activities in the cells 
transfected with the mutagenized  cDNA  never exceeded those 
of the endogenous baseline activities in mock-transfected 
cells. Thus, even though a truncated  mutant enzyme protein 
is synthesized, it  has  no  catalytic activity. 
Splicing of Gene Fragment-Northern  analysis showed that 
COS-1 cells transfected with either  the  “normal”  or  “mutant” 
genes generated a large quantity of RNA that hybridized to 
the full-length normal @-hexosaminidase a cDNA (Fig. 4). 
Although there were clear signs of degradation  perhaps  due 
to  the  abnormal  nature of the processed “mRNA,  the size of 
the main band was estimated  to be approximately 2 kb. The 
sum of exons 9 through 14 is 790 bp. The  approximately 800- 
bp segment of intron 8 at  the 5’ terminus is not expected to 
be spliced out, because it lacks the 5’ donor site. The  distance 
between the 5’ terminus of the  inserted gene sequence and 
the SV40 transcription  initiation  site in the vector is approx- 
imately 300 bp. Thus,  the  RNA observed on  the  Northern 
blotting was of the size expected if this  segment of the gene 
is spliced normally. Most  importantly,  no differences  between 
the normal and mutant were observed in repeated experi- 
ments. 
DISCUSSION 
Diagnostic studies in many laboratories have established 
convincingly that  the @-hexosaminidase a subunit allele that 
contains  the four-base insertion is responsible for approxi- 
mately two-thirds of Ashkenazi Jewish  patients with infantile 
Tay-Sachs disease (1, 16). The  insertion  is at 53 bases up- 
stream from the 3’ end of exon 11. This  mutant gene is known 
n c o.lr( Normal 0 Mutant = Mock 
GlcNAc  GlcNAc-SO, 
SUBSTRATE 
FIG 3. Expression of the catalytic activity of the normal 
and  mutant  &hexosaminidase a subunits  in COS-1 cells. The 
experimental details are described in the text. This figure presents 
means  of  duplicate samples. 
FIG. 4. Northern  blotting  analysis of the  processed RNA in 
COS-1 cells  transfected  with normal or mutant  8-hexosamin- 
idase a gene  segments. Technical  details are  described  in the text. 
COS-I cells transfected with the 3’-most 6-kb segment of the gene 
with or without  the  four-base-insertion  in exon 11 appear to process 
the transcripts as normally  expected. No quantitative or qualitative 
differences are detected  between the cells transfected  with the normal 
and  mutant  genes. The estimated  size at the arrow is 2 kb. 
to be transcribed normally (5). If the  primary  transcripts were 
then spliced normally to a stable mRNA, the  consequent  shift 
in  the  open  reading  frame would have  placed  a termination 
codon 9 bases  downstream of the  insertion,  thus  truncating 
the  protein  at  the carboxyl terminus from the normal 529 
amino acids to 430 amino acids. In reality, however, @-hex- 
osaminidase a mRNA derived from this allele and conse- 
quently its translation product is essentially undetectable. 
Thus,  this relatively minor  abnormality  in  the middle of an 
exon at 80% of the way toward  the carboxyl terminus of the 
protein may interfere  with  normal  transcript processing and/ 
or stability. The experiments described in this report were 
designed to  address  this question. 
The  main  observations  on expression of cDNA were (a) a 
cDNA with a sequence, which would have  resulted if the gene 
with  the four-base insertion were properly spliced, generates 
a stable mRNA, ( b )  the mRNA is  translated  to a truncated 
enzyme protein of the expected size but of reduced quantity, 
and  (c)  the polypeptide is not  further processed and nonfunc- 
tional  but  appears  to be  relatively stable. We interpret  these 
findings to  mean  that  the four-base insertion does not  desta- 
bilize processed mRNA  but  that  it may interfere with intra- 
nuclear processing and  transport of the  primary  transcript. 
Seemingly analogous situations are known among /3-globin 
gene mutations (17-21). In these instances, premature ter- 
mination codons appear  to affect intranuclear RNA process- 
ing  but  not  stability of cytoplasmic  mRNA, although  the levels 
of mRNA were significantly lower than normal in most cases. 
When  the  same codon  was mutated  either  to a termination 
codon or  to  another  translatable codon, the former  generated 
a lower mRNA level (20). In close examination, however, the 
examples of @-globin may or may not be comparable to  the 
four-base insertion  in  the /3-hexosaminidase a gene. The @- 
globin is much  smaller than @-hexosaminidase a (146 uersus 
529 amino acids), and the truncations in @-globin were all 
rather  drastic, located at positions 17, 39, and 43. The  Tay- 
Sachs gene with  the  premature  termination codon still codes 
a protein of 430 amino acids. In  this regard,  observations on 
a  series of complete a,-antitrypsin deficiency (Null  mutations) 
may be more comparable and suggest complex mechanisms 
(22-27). Normal  al-antitrypsin precursor has 418 amino acids. 
NullGranite Falls results from a  single-base  deletion  with  a  pre- 
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mature  stop codon at  residue 160  in  exon 2 (24).  mRNA may 
be negative (23) although  this was not  clear  with  the index 
case who had  another  mRNA-positive allele. NullBellinpham re- 
sults from  a nonsense  mutation  at residue 217 in  exon 3 and 
is  mRNA-negative  (25). NullMuttawa is caused by a  single-base 
insertion  at residue  353 with a stop codon at  residue 376 in 
exon 5 (26). This mutation generates normal-sized mRNA 
but  no  detectable  protein. NullH,,, results  from a two- 
base deletion at residue 318 in exon 4 with a stop codon a t  
residue 334 (27). When the mutant genomic clone was ex- 
pressed in  mouse hepatoma cells, it  generated a normal  quan- 
tity of mRNA  and a truncated  protein of reduced quantity. 
The  mutant  protein was glycosylated but was retained  within 
the endoplasmic reticulum. Within this limited number of 
examples, there  appears  to  be a  general trend  that  mRNA  is 
negative when the premature stop codon is located early 
toward  the 5’ terminus of the  protein. 
Fundamentally,  in  order  for  abnormal  premature  termina- 
tion codons to affect  processing of the  primary  transcript,  one 
must  postulate at least two improbable  intranuclear molecular 
mechanisms: (a )  a mechanism  that  can recognize and  distin- 
guish within  the  transcript  the  eventual  open  reading  frame 
from  the  other two frames, because closed frames have abun- 
dant  stop codons, and (6) a mechanism to  know normal sizes 
of open reading  frames so that  abnormal  premature  termina- 
tion codons are recognized as  such. 
The above consideration suggests that abnormal splicing 
and consequent degradation due to the four-base insertion 
might  still be the  most plausible explanation for the  absence 
of mRNA, even though  its  position  is fairly remote  from  the 
flanking  exon-intron  junctions. However, we were unable  to 
obtain  experimental evidence to  support  this possibility. The 
3’-most  6-kb  segment of the gene with  or  without  the  four- 
base  insertion  in  exon 11 appeared  to  be spliced  identically. 
Thus,  none of the  experimental  results so far  obtained  can 
explain how the  four-base  insertion  near  the middle of exon 
11 causes almost  total  absence of mRNA. We  should keep in 
mind, however, that  the splicing experiments were done  with 
a transient expression system, and that splicing can occur 
differently when the gene is stably  integrated  into  the genome 
(28).  Furthermore,  Libri et al. (29)  reported  that exon as well 
as intron sequences can  be  cis-acting  regulating  elements  for 
mutually exclusive alternative splicing. Evaluation of these 
factors would require construction of a complete mutant p- 
hexosaminidase a gene, which has  the  four-base  insertion  but 
is otherwise normal,  and  its  expression  in  stable  transfectants. 
The possibility of simultaneous  existence of another  abnor- 
mality  in  the  same allele that  might  actually  be responsible 
for  the absence of mRNA  still  remains. However,  Myerowitz 
and Costigan (4)  have  found  the following regions of the allele 
to  be normal: the  promoter region, all  exon-intron  junctions, 
the region of the polyadenylation signal, and all exon se- 
quences  except  the  four-base  insertion.  This leaves  only lim- 
ited regions within  the  primary  transcript where search for 
another  abnormality  can  be directed. 
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